Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Assets (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Assets data on record, last reported at $44.8 million in Q3 2025.

  • For Q3 2025, Assets fell 8.39% year-over-year to $44.8 million; the TTM value through Sep 2025 reached $44.8 million, down 8.39%, while the annual FY2024 figure was $38.3 million, 47.98% down from the prior year.
  • Assets reached $44.8 million in Q3 2025 per BTAI's latest filing, up from $25.8 million in the prior quarter.
  • Across five years, Assets topped out at $248.2 million in Q2 2022 and bottomed at $25.8 million in Q2 2025.
  • Average Assets over 4 years is $116.6 million, with a median of $82.3 million recorded in 2024.
  • Peak YoY movement for Assets: tumbled 64.2% in 2023, then dropped 8.39% in 2025.
  • A 4-year view of Assets shows it stood at $205.9 million in 2022, then crashed by 64.2% to $73.7 million in 2023, then crashed by 47.98% to $38.3 million in 2024, then grew by 16.83% to $44.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $44.8 million in Q3 2025, $25.8 million in Q2 2025, and $38.6 million in Q1 2025.